United States-based QuVa Pharma Inc has confirmed its ability to offer Dexamethasone Phosphate as a compounded sterile product in a ready-to-administer IV bag to treat hospitalised COVID-19 patients, in accordance with the FDA Drug Shortage guidelines, it was reported on Thursday.
The company's Dexamethasone Phosphate is a compounded sterile product (CSP) available as 6mg in 25ml 0.9% sodium chloride IV bag and is now available to be ordered.
Stuart Hinchen, co-founder and chief executive officer at QuVa, said, 'Dexamethasone phosphate has been listed on FDA's Drug Shortages list, as well as their list of compounded drugs for hospitalised COVID-19 patients. QuVa is committed to supporting hospitals as they advance quality patient care, and a ready-to-administer intravenous presentation will enable hospitals to meet their patient care needs while their pharmaceutical supply chain for this product improves.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval